{"mainPropery":{"diseaseId":7236,"diseaseName":"Ocular melanoma","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/7236/ocular-melanoma","synonyms":[],"synonyms-with-source":[],"identifiers":[{"identifierType":"UMLS","identifierId":"C0558356"}]},"diseaseCategories":[{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":672,"resourceName":"Ocular Melanoma Foundation","address1":"P.O. Box 29261","address2":"","address3":"","address4":"","address5":"","city":"Richmond","state":"VA","zip":"23242-0261","country":"United States","phone":"","tty":"","tollFree":"","fax":"","email":"http://www.ocularmelanoma.org/contact-us.htm#","url":"http://www.ocularmelanoma.org/home.htm#"},{"resourceID":4207,"resourceName":"A Cure In Sight","abbreviation":"","address1":"PO Box 58113  ","address2":"Raleigh, NC 27658-8113","address3":"or","address4":"4225 Solano Ave  ","address5":"","city":"Napa  ","state":"CA","zip":"94558","country":"United States","phone":"+1-(919) 885-5264 (East); +1-707-628-1253 (West)","tty":"","tollFree":"","fax":"","email":"contact@acureinsight.org","url":"https://acureinsight.org/","freeText":""},{"resourceID":4293,"resourceName":"Melanoma Research Alliance","abbreviation":"MRA","address1":"730 15th Street, NW","address2":"","address3":"","address4":"","address5":"","city":"Washington","state":"DC","zip":"20005","country":"United States","phone":"+1-202-336-8935","tty":"","tollFree":"","fax":"","email":" info@curemelanoma.org","url":"https://www.curemelanoma.org/","freeText":""}],"resource descriptions":[{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Ocular+melanoma%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Ocular melanoma. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":596,"resourceId":1333,"resourceName":"Intraocular melanoma","descriptionText":"The <a href='http://www.ocularmelanoma.org/patient-forum.htm# ' target='_blank'>Ocular Melanoma Foundation Patient Forum</a> is an interactive social network for patients, family members and health care providers to interact with one another.Â  Click on the link to read more about this forum.","resourceClassificationName":"Organizations","resourceClassificationSectionName":"Social Networking Websites"},{"id":598,"resourceId":1333,"resourceName":"Intraocular melanoma","descriptionText":"The <a href='http://www.jhu.edu/wctb/coms/index.htm ' target='_blank'>Collaborative Ocular Melanoma Study</a> or COMS for short, is a set of clinical trials designed to evaluate the treatments doctors use for their patients with choroidal melanoma. COMS clinical trials are funded by the National Eye Institute and the National Cancer Institute of the National Institutes of Health, and are being conducted at more than 40 medical centers in the United States and Canada.","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='http://www.nlm.nih.gov/medlineplus/ency/article/001022.htm' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1532,"resourceId":2163,"resourceName":"Social Security Administration","descriptionText":"The <a href='https://secure.ssa.gov/apps10/poms.nsf/lnx/0423022460' target='_blank'>Social Security Administration</a> has included this condition in their Compassionate Allowances Initiative. This initiative speeds up the processing of disability claims for applicants with certain medical conditions that cause severe disability. More information about <a href=\"http://www.ssa.gov/compassionateallowances/index.htm\" target=\"_blank\">Compassionate Allowances</a> and <a href=\"https://www.ssa.gov/benefits/disability/\" target=\"_blank\">applying for Social Security disability</a> is available online.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":1543,"resourceId":2171,"resourceName":"National Cancer Institute","descriptionText":"The <a href='http://www.cancer.gov/cancertopics/pdq/treatment/intraocularmelanoma' target='_blank'>National Cancer Institute</a> provides the most current information on cancer for patients, health professionals, and the general public.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1599,"resourceId":1333,"resourceName":"Intraocular melanoma","descriptionText":"The <a href='http://www.jhu.edu/wctb/coms/index.htm' target='_blank'>Collaborative Ocular Melanoma Study</a> or COMS for short, is a set of clinical trials designed to evaluate the treatments doctors use for their patients with choroidal melanoma. COMS clinical trials are funded by the National Eye Institute and the National Cancer Institute of the National Institutes of Health, and are being conducted at more than 40 medical centers in the United States and Canada.","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/DOID:1752' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2161,"resourceId":3369,"resourceName":"HealthWell Foundation","descriptionText":"The <a href='http://www.healthwellfoundation.org/melanoma' target='_blank'>HealthWell Foundation</a> provides financial assistance for underinsured patients living with chronic and life-altering conditions. They offer help with drug copayments, deductibles, and health insurance premiums for patients with specific diseases. The disease fund status can change over time, so you may need to check back if funds are not currently available.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":2162,"resourceId":3371,"resourceName":"The Assistance Fund","descriptionText":"<a href='https://tafcares.org/patients/covered-diseases/' target='_blank'>The Assistance Fund</a> provides various services, including education and financial aid, to help patients with a chronic or serious illness cover the cost of FDA-approved medications. Patients must be U.S citizens or permanent residents.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":2163,"resourceId":3372,"resourceName":"Good Days","descriptionText":"<a href='https://www.mygooddays.org/patients/diseases-covered/chronic-iron-overload' target='_blank'>Good Days</a> provides help to patients with life-altering conditions. Assistance includes help with the cost of medications and travel.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"}],"overviewQuestion":{"questionId":3828,"questionText":"What is ocular melanoma?","answerText":"<strong>Ocular melanoma (OM)</strong> is a cancer in pigment-producing cells of the <a href=\"http://www.cancer.gov/Common/PopUps/popImage.aspx?imageName=/images/cdr/live/CDR543553-750.jpg&amp;caption=Anatomy of the eye, showing the outside and inside of the eye including the sclera, cornea, iris, ciliary body, choroid, retina, vitreous humor, and optic nerve. The vitreous humor is a liquid that fills the center of the eye.\" target=_blank>eye</a>&nbsp;called melanocytes.&nbsp;&nbsp;&nbsp;Melanocytes are cells that produce the pigment melanin that colors the skin, hair, and eyes, as well as forms moles.&nbsp; There are four tissues in the eye in which melanoma can develop: <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002337.htm\" target=_blank>the uveal tract (uvea</a>); <a href=\"http://library.thinkquest.org/C005949/anatomy/conjunctiva.htm\" target=_blank>conjunctiva</a>; eyelid; and <a href=\"http://www.emedicinehealth.com/script/main/art.asp?articlekey=4658\" target=_blank>orbit</a>.&nbsp; The uvea - the middle layer&nbsp;within the eye&nbsp; - is divided into three main parts: the <a href=\"http://www.cancer.gov/common/popUps/popDefinition.aspx?id=CDR0000534221&amp;version=Patient&amp;language=English\" target=_blank>iris</a>, <a href=\"http://www.cancer.gov/common/popUps/popDefinition.aspx?id=CDR0000534222&amp;version=Patient&amp;language=English\" target=_blank>ciliary body</a>, and <a href=\"http://www.cancer.gov/common/popUps/popDefinition.aspx?id=CDR0000534223&amp;version=Patient&amp;language=English\" target=_blank>choroid</a>.&nbsp; Uveal melanoma, also called <a href=\"http://rarediseases.info.nih.gov/GARD/Condition/8621/Intraocular_melanoma.aspx\" target=_blank>intraocular melanoma</a>, is the most common ocular melanoma. Conjunctival melanoma manifests on the surface of the eye and has been increasing in incidence. Eyelid and primary orbital melanoma are the&nbsp;least common variants.[2748]","dateModified":"2013-01-14T14:19:00"},"basicQuestions":[],"references":[],"relatedDiseases":[],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[{"productId":121,"genericName":"Aldesleukin","tradeName":"Proleukin","tradeLink":"https://www.proleukin.com/","manufacturer":"","sponsor":"Chiron Corporation","indication":"Treatment of adults with metastatic melanoma.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/Proleukin","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a692009.html"}],"EncodedName":"Ocular_melanoma"}